Caregen Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2001-08-01
- Employees
- 192
- Market Cap
- -
- Website
- http://www.caregen.co.kr
Clinical Trials
7
Active:5
Completed:0
Trial Phases
2 Phases
Phase 1:2
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 3
5 (71.4%)Phase 1
2 (28.6%)Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Phase 1
Recruiting
- Conditions
- Age-related Wet Macular Degeneration
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Caregen Co. Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06132035
- Locations
- 🇺🇸
CBCC Global Research Site:005, Manchester, Connecticut, United States
🇺🇸CBCC Global Research Site:006, Deerfield Beach, Florida, United States
🇺🇸CBCC Global Research Site:007, Philadelphia, Pennsylvania, United States
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug
Phase 1
- Conditions
- Healthy
- Interventions
- Drug: CG-SpikeDown, intranasal formulationDrug: Vehicle (Placebo)Drug: Standard of core (type of therapy is depend of decide of the site)
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Caregen Co. Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05234320
News
No news found